Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-B0698A |
Brand: | MCE |
CAS: | 118081-34-8 |
MDL | MFCD08141796 |
---|---|
Molecular Weight | 446.46 |
Molecular Formula | C15H18N4O8S2 |
SMILES | O=C(C(N12)=CCS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=C\CC(O)=O)=O)C1=O)O.O.O |
Ceftibuten (Sch-39720) dihydrate, an antibiotic , is an orally active cephalosporin, possesses potent activity in vitro against a wide range of gram-negative and certain gram-positive pathogens [1] [2] .
Ceftibuten (Sch-39720) is highly active against Haemophilus influenza , Escherichia coli , Klebsiella sp., and Proteus sp. and moderately active against Serratia sp. and Streptococcus pyogenes . Ceftibuten is relatively inactive against enterococci and staphylococci and is only weakly active against Pseudomonas aeruginosa and obligate anaerobes. It is also stable in the presence of most β-lactamase-producing organisms except β Bacteroides fragilis . Ceftibuten is very active against strains of the family Enterobacteriaceae (mean MIC for 90% of strains=0.25 μg/ml) but less active against Campylobacterjejuni (mean MIC for 90% of strains=16.0 μg/ml) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Ceftibuten, a biologically stableβ-lactam antibiotic, has been shown to be transported by the small peptide transport system, to have relatively high affinity for the carrier and to show clear stereoselective and proton-gradient dependent transport characteristics in rat intestinal brush-border membrane vesicles [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00724256 | IRCCS Burlo Garofolo |
Pyelonephritis
|
July 2006 | Phase 3 |
NCT05488678 | Venatorx Pharmaceuticals, Inc.|National Institute of Allergy and Infectious Diseases (NIAID) |
Pharmacokinetics
|
October 12, 2022 | Phase 1 |
NCT04877379 | Venatorx Pharmaceuticals, Inc.|National Institute of Allergy and Infectious Diseases (NIAID) |
Healthy Subjects
|
June 8, 2021 | Phase 1 |
NCT05527834 | Venatorx Pharmaceuticals, Inc.|National Institute of Allergy and Infectious Diseases (NIAID) |
Pharmacokinetics
|
September 13, 2022 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 223.98 mM ; Need ultrasonic)
H 2 O : 100 mg/mL ( 223.98 mM ; ultrasonic and warming and heat to 80°C)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.2398 mL | 11.1992 mL | 22.3984 mL |
5 mM | 0.4480 mL | 2.2398 mL | 4.4797 mL |
10 mM | 0.2240 mL | 1.1199 mL | 2.2398 mL |
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
Add each solvent one by one: PBS
Solubility: 2.26 mg/mL (5.06 mM); Clear solution; Need ultrasonic
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.